NEW YORK, July 26, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced that the underwriters have exercised in full their option to purchase an additional 855,000 shares of common stock. The option to purchase additional shares is being exercised in connection with TG Therapeutics' previously announced public offering of 5,700,000 shares of its common stock at a price of $6.15 per share. As a result of the exercise, the total gross proceeds to TG Therapeutics from the offering are expected to be approximately $40.3 million, before deducting the underwriting discount and estimated offering expenses payable by the company. The closing of the purchase of the additional shares is expected to occur on or about July 26, 2013.
Roth Capital Partners, LLC, Ladenburg Thalmann & Co. Inc., and Brean Capital, LLC, are acting as joint book-running managers in the offering. National Securities Corporation is acting as co-manager in the offering.
The shares described above are being offered by TG Therapeutics pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC"). A prospectus relating to the offering has also been filed with the SEC and is available on the SEC's website at http://www.sec.gov . Copies of the prospectus supplement and accompanying base prospectus relating to this offering may also be obtained from Roth Capital Partners, LLC, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV